Apoptosis-related biomarkers sFAS, MIF, ICAM-1 and PAI-1 in serum of breast cancer patients undergoing neoadjuvant chemotherapy.

BACKGROUND Neoadjuvant chemotherapy improves surgical options and prognosis in patients with operable breast cancer. Predictive biomarkers are needed to choose the most effective therapy and to avoid unnecessary toxicity. PATIENTS AND METHODS We analyzed the courses of apoptosis-related serum biomarkers macrophage migration-inhibitory factor (MIF), soluble cell death receptor sFAS, soluble intercellular adhesion molecule (sICAM), plasminogen activator inhibitor 1 (PAI-1) as well as the oncological biomarkers carcino-embryonic antigen (CEA) and carbohydrate antigen 15-3 (CA15-3) in prospectively collected sera of 51 patients with locally confined breast cancer undergoing preoperative chemotherapy. As controls 31 healthy women, 13 patients with benign breast disease and 28 patients with metastasized breast cancer were included. RESULTS sFAS, MIF, CEA and CA15-3 showed significantly higher serum concentrations in patients with metastasized breast cancer than in healthy and benign controls. Additionally, sFAS and MIF discriminated between locally confined breast cancer and healthy controls with an area under the curve (AUC) in receiver operating characteristic (ROC) curves of 73.4% and 70.7%. After neoadjuvant chemotherapy, 38 patients achieved complete (N=9) or partial (N=29) remission, while 13 patients had no change of disease. Pretherapeutic levels of MIF were considerably higher in non-responsive patients (p=0.082). In addition, post-therapeutic sICAM and CA15-3 levels were higher in patients without complete remission. CONCLUSION Apoptosis-related biomarkers are valuable markers in breast cancer patients and show potential for early estimation of the efficiency of neoadjuvant chemotherapy.

[1]  G. Daskalopoulos,et al.  Soluble adhesion molecules E-cadherin, intercellular adhesion molecule-1, and E-selectin as lung cancer biomarkers. , 2010, Chest.

[2]  A. Jemal,et al.  Global Patterns of Cancer Incidence and Mortality Rates and Trends , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[3]  L. K. Ovchinnikova,et al.  Cancer and Soluble FAS , 2009, Bulletin of Experimental Biology and Medicine.

[4]  S. Leung,et al.  Serum macrophage migration‐inhibitory factor as a diagnostic and prognostic biomarker for gastric cancer , 2009, Cancer.

[5]  E. Dahl,et al.  Dual role of macrophage migration inhibitory factor (MIF) in human breast cancer , 2009, BMC Cancer.

[6]  M. Untch,et al.  Recent advances in systemic therapy. Advances in neoadjuvant (primary) systemic therapy with cytotoxic agents , 2009, Breast Cancer Research.

[7]  E. Winer,et al.  Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. Stieber,et al.  Clinical use of circulating nucleosomes , 2009, Critical reviews in clinical laboratory sciences.

[9]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[10]  Sayan Mukherjee,et al.  Do serum biomarkers really measure breast cancer , 2009 .

[11]  Pil Je Park,et al.  The multiplex bead array approach to identifying serum biomarkers associated with breast cancer , 2009, Breast Cancer Research.

[12]  H. Nielsen,et al.  National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. , 2008, Clinical chemistry.

[13]  B. Sobel,et al.  The effect of plasminogen activator inhibitor type 1 on apoptosis , 2008, Thrombosis and Haemostasis.

[14]  Qin He,et al.  Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. , 2008, Gynecologic oncology.

[15]  J. Marks,et al.  Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer , 2008, Breast Cancer Research.

[16]  J. Bernhagen,et al.  Macrophage Migration Inhibitory Factor in Cardiovascular Disease , 2008, Circulation.

[17]  R. Gray,et al.  Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non–Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—an Eastern Cooperative Oncology Group Study , 2008, Clinical Cancer Research.

[18]  Y. Iwadate,et al.  High serum level of plasminogen activator inhibitor-1 predicts histological grade of intracerebral gliomas. , 2008, Anticancer research.

[19]  E. Repasky,et al.  Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update , 2008, Cancer Immunology, Immunotherapy.

[20]  R. Bast,et al.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  O. De Wever,et al.  Soluble cadherins as cancer biomarkers , 2007, Clinical & Experimental Metastasis.

[22]  I. Thompson,et al.  Assessment of 54 Biomarkers for Biopsy-Detectable Prostate Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.

[23]  F. Puglisi,et al.  Markers of the uPA system and common prognostic factors in breast cancer. , 2007, American journal of clinical pathology.

[24]  W. Naumnik,et al.  Serum levels of sFas and sFasL during chemotherapy of lung cancer. , 2007, Experimental oncology.

[25]  N. Dalay,et al.  Macrophage Migration Inhibitory Factor in Cancer , 2007, Cancer investigation.

[26]  B. Kramer,et al.  Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  A. Kremer,et al.  Nucleosomes in Colorectal Cancer Patients during Radiochemotherapy , 2006, Tumor Biology.

[28]  F. Lokiec,et al.  Variations of soluble fas and cytokeratin 18-Asp 396 neo-epitope in different cancers during chemotherapy. , 2006, Anticancer research.

[29]  J. Bernhagen,et al.  MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis , 2006, Nature Reviews Drug Discovery.

[30]  Andreas Makris,et al.  Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Yan Ding,et al.  Increased epithelial and serum expression of macrophage migration inhibitory factor (MIF) in gastric cancer: potential role of MIF in gastric carcinogenesis , 2006, Gut.

[32]  Kai-Ping Chang,et al.  Cancer cell‐secreted proteomes as a basis for searching potential tumor markers: Nasopharyngeal carcinoma as a model , 2005, Proteomics.

[33]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[34]  A. Kremer,et al.  Nucleosomes in Pancreatic Cancer Patients during Radiochemotherapy , 2005, Tumor Biology.

[35]  K. Feldmann,et al.  Circulating Nucleosomes Predict the Response to Chemotherapy in Patients with Advanced Non–Small Cell Lung Cancer , 2004, Clinical Cancer Research.

[36]  S. Ancoli-Israel,et al.  The Effects of Standard Anthracycline-Based Chemotherapy on Soluble ICAM-1 and Vascular Endothelial Growth Factor Levels in Breast Cancer , 2004, Clinical Cancer Research.

[37]  L. Zhang,et al.  Evaluation of sICAM-1, sVCAM-1, and sE-Selectin levels in patients with metastatic breast cancer receiving high-dose chemotherapy. , 2004, Stem cells and development.

[38]  A. Cattelan,et al.  Differential levels of soluble intercellular adhesion molecule-1 (sICAM-1) in early breast cancer and benign breast lesions , 1999, Breast Cancer Research and Treatment.

[39]  T. Calandra,et al.  Macrophage migration inhibitory factor: a regulator of innate immunity , 2003, Nature Reviews Immunology.

[40]  S. Sheen-Chen,et al.  Circulating Soluble Fas in Patients with Breast Cancer , 2003, World Journal of Surgery.

[41]  C. Malone,et al.  Soluble adhesion molecules (E-selectin, ICAM-1 and VCAM-1) in breast carcinoma. , 2002, European journal of cancer.

[42]  M. Dowsett,et al.  The biology of neoadjuvant chemotherapy for breast cancer. , 2002, Endocrine-related cancer.

[43]  J. Bernhagen,et al.  Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. , 2002, Microbes and infection.

[44]  K. Meyer-Siegler,et al.  Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma , 2002, Cancer.

[45]  C. Wiltschke,et al.  Soluble ICAM-1 in breast cancer: clinical significance and biological implications , 2001, Cancer Immunology, Immunotherapy.

[46]  V. Vasioukhin,et al.  The Origin and Mechanism of Circulating DNA , 2000, Annals of the New York Academy of Sciences.

[47]  M. Toi,et al.  Circulating soluble Fas concentration in breast cancer patients. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  John Calvin Reed.  Dysregulation of apoptosis in cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  I. Adachi,et al.  Serum levels of soluble intercellular adhesion molecule-1 and E-selectin in metastatic breast carcinoma: correlations with clinicopathological features and prognosis. , 1999, International journal of oncology.

[50]  Anna L. Brown,et al.  Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  P. Walker,et al.  Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. , 1997, Journal of immunology.

[52]  S. Nagata,et al.  Apoptosis by Death Factor , 1997, Cell.

[53]  L. Owen-Schaub,et al.  Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. , 1996, Cancer research.

[54]  C. Ware,et al.  Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis? , 1995, Cancer letters.

[55]  P. Krammer,et al.  Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemias. , 1995, Blood.

[56]  C. Winterford,et al.  Apoptosis. Its significance in cancer and cancer Therapy , 1994, Cancer.

[57]  S. Koyama.  Immunosuppressive Effect of Shedding Intercellular Adhesion Molecule 1 Antigen on Cell‐mediated Cytotoxicity against Tumor Cells , 1994, Japanese journal of cancer research : Gann.

[58]  B. Zetter,et al.  Adhesion molecules in tumor metastasis. , 1993, Seminars in cancer biology.

[59]  Michael Loran Dustin,et al.  Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). , 1986, Journal of immunology.